Prevalence of Precancerous Lesions Based on Digital Cervicography with VIA/VILI among Women Positive for High-Risk Human Papillomavirus Serotypes: A Screening Center-Based Study in Cameroon

Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. Objectives: Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. Methodology: The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaoundé, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values Results: We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. Conclusion: A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity;HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a decreasing order of oncogenicity.

Distribution of High-Risk Human Papillomavirus Genotypes among Women with Colposcopic Diagnosis of Cervical Intraepithelial Neoplasia in Bangladesh

Background: The incidence of cervical cancer is high in Bangladesh and there is a high prevalence of preinvasive lower genital tract disease among women of reproductive age. Persistent high-risk Human Papilloma Virus (HPV) infection is the main underlying cause of cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN). Objective: The aim of the study was to identify the subtypes of high-risk HPV infection among women with the colposcopic diagnosis of cervical intraepithelial neoplasia in Bangladesh. Methods: This cross-sectional observational study was conducted in the colposcopy clinic of Dhaka Medical College Hospital over a six-month period. A total of 100 participants were enrolled. Married women, between 30 - 60 years of age with colposcopically diagnosed cervical intra epithelial neoplasia were enrolled. Women with chronic illness, pregnancy, and women unable to consent were excluded from this study. After counselling, colposcopically directed punch biopsies were taken from each CIN case concurrently with high-risk HPV testing by polymerase chain reaction (PCR). Results: The mean age of the patients was 38.69 (SD ±7.76) years. CIN 1 was diagnosed in 57% of participants, while 24% had CIN II and 19% had CIN III lesions. High-risk HPV was present in 52 patients. HPV 16 was the most common identified in 28 (53.84%) and HPV 18 was the second most common with 20 (38.46%) either singly or in combination with other high-risk subtypes. The other HPV strains, HPV 31, 33, 35, 52, 56 and 58, were also detected either as mono or co-infections. Out of the 52 HPV positive cases, 29 (55.8%) had mono infection and 23 (44.2%) had co-infection with several subtypes. The highest incidence (50%) of oncogenic HPV infections was present among women aged 35 - 45 years. Risk factors associated with HPV positive cases were high parity (P 0.05), early age at marriage (P = 0.754) and early age of first child. Conclusion: This study identified a high prevalence of HPV 16 and 18 genotypes. HPV vaccination with the current 9-valent HPV vaccine, which contains HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Will be an effective public health measure to eradicate cervical cancer in Bangladesh.

Analysis of Human Papillomavirus Infection in Cervical Exfoliated Cells

To screen patients with early cervical lesions by analyzing the infection of high-risk Human papillomavirus (HR-HPV). Research Methods: The cervical exfoliated cell specimens and their clinical data were collected. The HPV infection types of the collected specimens were detected by fluorescence quantitative PCR, and the correlation between HPV infection and clinicopathological features was analyzed statistically. Results: 725 cases were HR-HPV positive from 2605 cases, including 15 high-risk types of HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68. Different histological types ranged from NILM to HSIL, and the positive rate of HPV showed an increasing trend with the aggravation of cervical lesions. Conclusion: The positive rate of 15 high-risk HPV types in the collected specimens was 27.8%. Patients with early cervical lesions could be screened for 15 high-risk HPV infection types.

Efficacy of 2LPAPI®, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection

Human papillomaviruses (HPVs) are well known for being linked to the development of cervical cancers, most of them being caused by the high-risk (HR) oncogenic genotypes, mainly 16 and 18. The efficacy of 2LPAPI® (Labo’Life), a micro-immunotherapy homeopathic drug, has been evaluated in HR-HPV infected women (n = 18), in a private gynecology practice, by comparing them to an untreated control group (n = 18). Patients were 20 to 45 years old and had cytology with Atypical Squamous Cells of Undetermined Significance (ASCUS) or Low grade Superficial Intra Lesions/ Cervical Intraepithelial Neoplasia Grade I (LSIL/CINI). Patients freely chose to be treated with the drug or not. Those deciding not to take the drug remained untreated and were followed as a control group. The drug was taken at the regimen of one capsule per day during 6 months. HR-HPV and cytology were evaluated at 6 and 12 months. After 12 months, HR-HPV was cleared in 78% of the patients taking the drug versus 44% in those not taking it (p = 0.086). In patients over 25 years, HR-HPV clearance in the treated group was significantly higher (81.3%) than in the control group (20%) (p = 0.004). The difference in the regression of the lesion grades almost reached statistical significance (p = 0.053). This follow-up confirms that the micro-immunotherapy drug 2LPAPI® is a safe and effective therapeutic approach to treat HR-HPV cervical lesions in women over 25 years.

Prevalence and Determinants of High-risk HPV Infection among 11549 Women from an Opportunistic Screening in Hubei Province

High-risk human papillomavirus (hrHPV) infection plays an important role in the development of cervical intraepithelial neoplasia and cervical cancer.A total of 11 549 women were enrolled from the Maternal and Child Health Hospital of Hubei Province.Each participant accepted hrHPV testing and completed a self^administered questionnaire about basic information and potential risk factors.The univariable and multivariable logistic regression model was used to explore the associations between variants and hrHPV infection.Our results showed that hrHPV prevalence was 16.09% in Hubei Province,among which,hrHPV was more likely to be positive in women aged 51 years or above (OR=1.65,95% CI:1.28-2.14),and in women who had symptoms of bleeding after intercourse (OR=1.32,95% CI:1.17-1.50),had first sexual intercourse at the age of 18 years or below (OR=1.33,95% CI:1.07-1.64),had at least three male sexual partners (OR=2.50,95% CI:2.07-3.03),and who had been diagnosed with sexually transmitted infections (OR=1.50,95% CI:1.12-2.03).Married women (OR=0.66,95% CI:0.55-0.78) and women who frequently used condoms (OR=0.75,95% CI:0.67-0.84) had a relatively lower hrHPV prevalence.This study confirms that hrHPV infection was associated with age,marital status,symptoms of intercourse bleeding,history of sexually transmitted infections,and sex-related behaviors.Above all,this study provides a baseline database prior to obtaining vaccinations for dynamic tracking of the changes in hrHPV prevalence.

Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis

Viral infections contribute to approximately 12%of cancers worldwide,with the vast majority occurring in developing countries and areas.Two DNA viruses,Epstein-Barr virus(EBV) and human papillomavirus(HPV),are associated with38%of all virus-associated cancers.The probability of one patient infected with these two distinct types of viruses is increasing.Here,we summarize the co-infection of EBV and HPV in human malignancies and address the possible mechanisms for the co-infection of EBV and HPV during tumorigenesis.

Relevant Frequency of Multiple Infections with High- and Low-Risk HPV Genotypes among Mexican Women Attending a Tertiary Care Hospital

Aims: To assess the frequency and the main HPV genotypes circulating among a group of women attending at a third level Hospital in Mexico City. Methods: A cross-sectional and descriptive study was performed in a group of 143 female outpatients of the Gynecology and Obstetrics Service at the National Institute of Perinatology of Mexico. Cervical swabs were taken from participants and subjected to simultaneous detection/genotyping of HPV by Linear Array Genotyping Test (Roche Molecular Systems). Mann-Whitney U, median and/or Square Chi tests were used to compare socio-demographical features between HPV-infected and uninfected women. Results: A total of 66 women (46.2%) had HPV infection. Overall, 112 genotypes were detected either as single infections (45.5%) or multiple genotype infections (54.5%). The cumulated frequency of multiple infections with high-/low- and high-/high-risk HPV genotypes was 63.9 %. The most frequent high-risk genotypes were HPV52 HPV58 and HPV51, whereas the most frequent low-risk genotypes were HPV6, HPV53 and HPV84. Infected women were significantly younger and have less stable partner relationships than uninfected women (p < 0.05). Conclusion: A relevant frequency of mixed infections with high- and low-risk HPV genotypes, other than those considered most prevalent worldwide, was observed. Most circulating high-risk genotypes among the women of this study are not covered by commercial vaccine formulations.

Retinoic acid receptor beta promoter methylation and risk of cervical cancer

Cervical cancer is one of the leading causes of death in women worldwide, particularly in developing countries. Human papillomavirus has been reported as one of the key etiologic factors in cervical carcinoma. Likewise, epigenetic aberrations have ability to regulate cancer pathogenesis and progression. Recent research suggested that methylation has been detected already at precancerous stages, which methylation markers may have significant value in cervical cancer screening. The retinoic acid receptor beta (RARβ) gene, a potential tumor suppressor gene, is usually expressed in normal epithelial tissue. Methylation of CpG islands in the promoter region of the RARβ gene has been found to be associated with the development of cervical cancer. To investigate whether RARβ methylation is a potential biomarker that predicts the progression of invasive cancer, we reviewed 14 previously published articles related to RARβ methylation. The majority of them demonstrated that the frequency of RARβ promoter methylation was significantly correlated with the severity of cervical epithelium abnormalities. However, methylation of a single gene may not represent the best approach for predicting disease prognosis. Analyzing combinations of aberrant methylation of multiple genes may increase the sensitivity, and thus this approach may serve as a better tool for predicting disease prognosis.

Risk Factors of Cervical Carcinoma and Countermeasures against Them in Mountainous Area of Wufeng County, China

Cases (n=44) with squamous cell cervical cancer (SCCA) and age-matched healthy controls (n=176) were analyzed. Significant difference due to human papillomavirus (HPV) infection, ages at the first marriage, ages at the first sexual intercourse, ages at the first birth given to baby, number of gravidities, number of deliveries, Body Mass Index (BMI), education level of women and their husbands (p<0.05) was observed. According to multivariate logistic regression analysis, four factors have entered the model (p<0.05), including HPV infection [OR (odds ratio)=26.13, 95%CI (confidence interval)=9.40?72.60], education level of women (OR=0.41, 95%CI=0.21?0.79), education level of spouses (OR=0.45, 95%CI=0.22?0.94), BMI (OR=0.73, 95%CI=0.57?0.93). Moreover, HPV infection is relative to education level of women (r=?0.14), and their spouses (r=?0.21), age at the first marriage (r=?0.20), age at the first birth given to baby (r=?0.20) and BMI (r=?0.15).

The effect of HPV infection on mental health status in women

Human papillomavirus(HPV)infection is one of the most common sexually transmitted infections globally,and its close association with the development of cervical cancer has become a major public health concern.HPV infection not only leads to physical health problems,but also has an impact on a woman’s mental health,such as:severe anxiety,fear,depression,negativity,and other psychological distress.The purpose of this review is to systematically summarize the current knowledge on this topic and to explore its current development in accordance with the PRISMA guidelines.We can provide interventions that may alleviate or even eliminate psychological problems in women,depending on their psychological characteristics.A total of 82 records were included in the study,including 37 papers on the effect of HPV infection on the mental health status of women and 45 studies on the effect of implementing interventions on the mental health of patients with HPV infection.The results show that HPV infection can make women produce anxiety,depression,shame,low self-esteem and other negative psychological.However,active and proper medical treatment,psychological counseling and support,and strengthening health education have positive effects on HPV-infected women,and can promote the mental health of HPV-infected women.

宫颈癌筛查妇女高危型人乳头瘤病毒感染现状及影响因素研究:基于成都市45万人群

背景宫颈癌是女性常见恶性肿瘤之一,其病因明确,通过规范筛查可以有效降低宫颈癌发病率。人乳头瘤病毒(HPV)检测是WHO推荐的首选宫颈癌筛查方法,了解成都市高危型人乳头瘤病毒(hrHPV)感染状况,对优化成都市宫颈癌筛查方案具有重要意义。目的分析成都市35~64岁参加宫颈癌筛查人群的hrHPV感染现状和宫颈病变患者的hrHPV亚型感染分布情况,探讨hrHPV阳性检出率的相关影响因素。方法从“成都市育龄妇女生殖健康数据库”收集2023年参加成都市免费宫颈癌筛查的459433例个案数据,分析不同hrHPV基因型感染总体分布情况以及宫颈病变患者的hrHPV亚型感染分布情况,比较不同特征人群hrHPV感染情况,并构建多水平Logistic回归模型分析hrHPV检出阳性情况的相关因素。结果459433例中,hrHPV阳性检出率为11.65%(53509/459433),hrHPV感染随年龄的增长呈上升趋势(χ_(趋势)^(2)=1501.082,P<0.001)。82.39%(131/159)的宫颈癌患者感染HPV 16或18亚型,以单纯感染HPV 16亚型为主(52.20%,83/159)。多水平Logistic回归分析结果显示,年龄、文化程度、婚姻状况、绝经状态、避孕方式、妊娠次数、分娩次数为hrHPV阳性检出情况的影响因素(P<0.05)。结论成都市女性hrHPV阳性检出率略低于全国平均水平。在筛查过程中,要重视健康教育与随访工作,特别是对HPV 16或18亚型阳性者的后续随访工作。开展宫颈癌筛查宣传工作时应特别关注年长者、文化程度较低者、未婚或离异/丧偶者、已绝经者、未避孕或采用避孕套外的其他避孕方式者、妊娠或分娩2次以上者等重点人群,加强宫颈癌防治核心知识、生殖健康知识等的宣传,提高妇女健康素养。

子宫颈癌患者HR-HPV感染及其亚型分布情况分析

目的:分析子宫颈癌患者高危型人乳头状瘤病毒(high-risk human papillomavirus,HR-HPV)感染情况及HR-HPV亚型分布情况。方法:研究纳入咸宁市妇幼保健院2020年2月—2024年1月临床收治的子宫颈癌患者322例为对象,采用HR-HPV核酸扩增分型检测试剂盒检测HR-HPV感染情况。采用PCR-反向斑点杂交技术检测患者宫颈细胞中HR-HPV不同亚型,同时采用全自动微生物鉴定仪检测并比较HR-HPV感染组、非HR-HPV感染组的阴道细菌感染情况。结果:322例子宫颈癌患者中,HR-HPV感染共247例,占比76.71%;HR-HPV感染子宫颈癌患者中,HR-HPV 16型感染率最高,为48.29%(127/263),HR-HPV 18型(15.36%)、31型(7.98%)、33型(6.46%)分别排名第二、第三、第四位。247例HR-HPV感染患者中,HR-HPV多重感染共16例;322例子宫颈癌患者中,HR-HPV感染组患者阴道细菌感染率(79.76%)显著高于非HR-HPV感染组(41.33%),差异有统计学意义(χ^(2)=41.091,P<0.05)。结论:子宫颈癌患者HR-HPV感染率较高,以HR-HPV 16型、18型最为常见,且HR-HPV感染子宫颈癌患者阴道细菌感染率高于非HR-HPV感染子宫颈癌患者。

名中医王国华从“虚、毒、瘀”辨治高危型人乳头瘤病毒感染经验

高危型人乳头瘤病毒(HR-HPV)持续感染可造成癌前病变、宫颈癌、宫颈上皮内瘤变等疾病,是目前妇科常见疾病之一。西医治疗HR-HPV感染效果有一定局限性。王国华教授临证发现HR-HPV感染多与“虚、毒、瘀”互结有关,认为虚实错杂是其病机本质。紧扣“虚”为HR-HPV感染之发病基础,“毒”为HR-HPV感染之致病关键,“瘀”为HR-HPV感染之病情转枢,认为“虚、瘀、毒”贯穿HR-HPV感染发病始终,自拟益气解毒化瘀汤加减以扶正祛邪,巧用经验对药,灵活加减,治疗同时注重形神同调,身心合治,疗效显著。

保妇康栓联合人干扰素α2b阴道泡腾片治疗宫颈高危型人乳头瘤病毒感染的临床疗效观察

目的探讨保妇康栓与人干扰素α2b泡腾片联合用药干预宫颈高危型人乳头瘤病毒(HR-HPV)感染的临床疗效。方法选取2023年1月—12月于武威市凉州医院就诊的140例宫颈HR-HPV病毒感染患者,依据随机数字表法将140例患者分为试验组和对照组,各70例。评估临床参数包括HR-HPV转阴率、总有效率、临床症状及体征改变、不良事件发生情况。结果与对照组比较,治疗后试验组HPV转阴率、总有效率更高(均P<0.05);试验组在改善患者临床症状方面表现更佳,其中试验组症状、体征总评分及阴部瘙痒评分更低(均P<0.05),阴道分泌物、性交出血、宫颈糜烂样改变、宫颈肥大或息肉评分也低于对照组(P>0.05);试验组的不良反应发生率更少(P<0.05)。结论保妇康栓联合人干扰素α2b阴道泡腾片用药可有效促进HPV病毒的清除,使得HPV转阴,改善临床症状及体征,且安全性较高。

阴道微生态与宫颈HR-HPV感染及宫颈病变关系的研究进展

高危型人乳头瘤病毒(HR-HPV)感染是导致宫颈上皮瘤变(CIN)及宫颈癌的关键因素。阴道内环境在正常情况下由于各菌群的动态平衡而处于稳定状态,由此构成女性生殖系统健康的重要基础,其中乳酸杆菌为优势菌群,在各种致病因素的作用下,各菌群间此消彼长,平衡状态由此被打破,导致阴道炎症病发率和HR-HPV感染率上升,并引发一系列宫颈病变,如无有效预防及干预手段,将进一步发展为宫颈癌。本文综述阴道微生态与宫颈HR-HPV感染及宫颈病变的关系的最新研究成果,以期为临床降低HR-HPV感染率及干预宫颈病变提供一定借鉴。

宫颈锥切术联合三元融合蛋白治疗宫颈HSIL合并高危型人乳头瘤病毒感染的临床疗效

目的:探讨宫颈锥切术联合三元融合蛋白(MBP-SERPINA-IFNκ,MSIK)治疗宫颈高级别鳞状上皮内病变(high-grade cervical lesions,HSIL)合并高危型人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)感染的临床效果。方法:选取2019年08月至2021年07月我院收治的186例HSIL患者,采用随机数字表法分为MSIK组(n=93)和对照组(n=93),两组均接受宫颈锥切术治疗,对照组术后非经期阴道推入干扰素α-2β凝胶,隔日一次,10次/疗程,MSIK组术后非经期阴道推入MSIK,14 d/疗程,均治疗3个疗程。比较两组患者治疗前后不同时间点TCT异常率及HR-HPV转阴率,比较两组治疗前后临床症状评分改变、治疗期间不良反应,比较两组治愈率及复发率。结果:随访期间两组HR-HPV转阴率呈升高趋势,且随访9、12个月两组HR-HPV转阴率均较随访3个月时升高(P<0.05);随访3、6、9、12个月时,MSIK组HR-HPV转阴率均高于对照组(P<0.05)。随访3、6、9、12个月,两组TCT异常率均明显低于治疗前,且MSIK组低于对照组(P<0.05)。治疗后两组临床症状评分较治疗前降低,且MSIK组更低(P<0.05)。MSIK治疗期间不良反应发生率为3.23%,低于对照组的10.75%(P<0.05)。MSIK组治愈率为97.85%,高于对照组的81.72%(P<0.05);随访12个月MSIK组无复发情况,与对照组复发率比较差异有统计学意义(P<0.05)。结论:宫颈锥切术联合MSIK治疗HSIL合并HR-HPV感染可有效提高转阴率,且治疗效果确切、复发率低,值得临床推广。

早期宫颈癌术后HPV持续感染的危险因素分析

目的分析早期宫颈癌根治术后高危型人乳头瘤病毒(HR-HPV)持续感染的相关危险因素。方法选取2021年1月至2023年11月之间,在昆明市妇幼保健院行开腹或腹腔镜下宫颈癌根治术的159例早期宫颈癌患者,根据术后1a返院复查HR-HPV持续感染情况分为2组:HR-HPV阳性组(n=41)和HR-HPV转阴组(n=118)。对2组患者的一般资料、阴道微生态情况、手术入路途径、术后病检结果等分析,研究早期宫颈癌患者术后HR-HPV持续阳性的相关危险因素。结果2组的单因素和多因素回归分析显示,绝经、手术期别晚、阴道微生态失调/亚失调是早期宫颈癌患者术后HR-HPV持续阳性的危险因素(P<0.05),而腹腔镜微创手术不是其危险因素。其中阴道微生态异常OR为12.574,绝经OR为3.510。结论绝经、阴道微生态失调为影响早期宫颈癌患者术后HR-HPV清除的重要危险因素。

保妇康栓联合臭氧治疗宫颈高危型人乳头瘤病毒感染的应用效果

目的观察宫颈高危型人乳头瘤病毒(HR-HPV)感染采用保妇康栓联合臭氧治疗的应用效果。方法选取2018年3月至2020年12月在南昌大学第四附属医院妇科检查中HPV检测为阳性的120例患者作为研究对象,根据随机数字表法分为试验组(60例)和对照组(60例)。对照组采用保妇康栓治疗,试验组采用保妇康栓联合臭氧治疗,两组共治疗3个疗程。比较两组患者的临床疗效、HPV转阴率、血清肿瘤坏死因子α(TNF-α)水平,白细胞介素-6(IL-6)水平、转化生长因子-β(TGF-β)水平和不良反应总发生率。结果试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05);试验组HR-HPV转阴率高于对照组,差异有统计学意义(P<0.05);试验组治疗后TNF-α、TGF-β水平低于对照组,IL-6水平高于对照组,差异有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论对宫颈HR-HPV患者采用保妇康栓联合臭氧治疗,效果确切,能够提高HPV转阴率,且安全性较高,值得临床推广应用。

不同治疗方案对宫颈高危型HPV感染患者的治疗效果分析

目的:探讨多种治疗方案对宫颈高危型人乳头瘤病毒(HPV)感染患者的临床治疗效果,为HPV患者的临床治疗提供新思路。方法:采用回顾性研究方法纳入2022年1月—2023年1月在宜昌市中心人民医院治疗的宫颈高危型HPV感染患者501例,根据患者选取的治疗方法分为三组,A组患者给予保妇康栓治疗(n=167),B组患者给予重组人干扰素α-2b凝胶治疗(n=167),C组给予抗HPV生物蛋白敷料治疗(n=167)。比较三组HPV患者治疗有效率、HPV-DNA水平、治疗后HPV阳性率和治疗过程中不良反应发生率,评价临床治疗效果。结果:C组患者治疗总有效率明显高于A组(90.42%vs 74.85%)和B组(90.42%vs 77.25%)(均P<0.05)。三组患者治疗3个月及6个月HPV-DNA水平较治疗前明显下降,且治疗3个月及6个月时,C组患者的HPV-DNA水平较A组和B组明显降低(均P<0.05)。治疗后C组HPV阳性率明显低于A组(6.60%vs 22.75%)和B组(6.60%vs 20.96%)(均P<0.05)。三组患者不良反应发生情况无明显统计学差异(P>0.05)。结论:抗HPV生物蛋白敷料对于宫颈高危型HPV感染患者的治疗效果优于保妇康栓及重组人干扰素α-2b凝胶,且不良反应发生少,值得临床上进一步推广。

血清Th1/Th2、Hmga1、PKM2表达水平及其联合HPV诊断宫颈癌的价值

目的探讨辅助性T细胞1(Th1)/辅助性T细胞2(Th2)、高迁移率族蛋白A1(Hmga1)、丙酮酸激酶M2型(PKM2)水平及联合人乳头状瘤病毒(HPV)对宫颈癌的诊断价值。方法选取2022年3月至2023年3月在河南省中医院就诊的186例宫颈疾病患者作为研究对象,根据疾病类型分为宫颈炎组(n=62)、宫颈癌前病变组(n=58)和宫颈癌组(n=66),另选取60例同期健康体检者作为对照组,比较四组及宫颈癌前病变组和宫颈癌组合并、未合并HPV感染患者入院时Th1/Th2因子[血清干扰素γ(IFN-γ)、白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)]、Hmga1、PKM2水平,分析血清Th1/Th2、Hmga1、PKM2水平表达与肿瘤病理特征的关系及联合HPV对宫颈癌合并HPV感染的诊断价值。结果四组受检者入院(体检)时的血清IFN-γ、IL-2、IL-4、IL-10、Hmga1、PKM2水平比较,宫颈癌组>宫颈癌前病变组>宫颈炎组>对照组,差异均有统计学意义(P<0.05);与未合并HPV感染患者比较,宫颈癌前病变组、宫颈癌组合并HPV感染患者入院时的血清IFN-γ、IL-2、IL-4、IL-10、Hmga1、PKM2水平较高,差异均有统计学意义(P<0.05);不同肿瘤分化程度、临床分期、有无淋巴结转移宫颈癌合并HPV感染患者入院时的血清IFN-γ、IL-2、IL-4、IL-10、Hmga1、PKM2水平比较差异均有统计学意义(P<0.05);HPV感染对宫颈癌诊断灵敏度为84.85%(54/66),特异度为72.41%(16/28),准确度为56.45%(70/124);血清IFN-γ、IL-2、IL-4、IL-10、Hmga1、PKM2、HPV感染对宫颈癌、宫颈癌前病变诊断AUC分别为0.761、0.730、0.745、0.806、0.819、0.707、0.786,HPV感染联合各血清指标诊断AUC为0.908,大于单一指标诊断。结论血清Th1/Th2、Hmga1、PKM2水平检测对宫颈癌具有一定的诊断价值,临床可通过其联合HPV感染情况早期辅助诊断宫颈病变,为临床针对性制定干预方案提供参考。